BBIO - BridgeBio Pharma Shares One Year Data From Dwarfism Candidate | Benzinga
Tuesday, BridgeBio Pharma Inc (NASDAQ:BBIO) announced sustained results from the PROPEL 2 Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, a disorder of bone growth that causes the most common type of dwarfism.
The data demonstrated continued efficacy and an encouraging safety profile.
Infigratinib is an oral small molecule designed to inhibit FGFR3 signaling and target achondroplasia and hypochondroplasia at their ...